Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome.
Fletcher, Mary A, Rosenthal, Martin, Antoni, Michael et al. · Behavioral and brain functions : BBF · 2010 · DOI
Quick Summary
This study measured a stress-related substance called neuropeptide Y (NPY) in the blood of ME/CFS patients and compared it to healthy people and people with Gulf War Illness. The researchers found that ME/CFS patients had significantly higher NPY levels, and these levels correlated with how severe their symptoms were—including stress, depression, fatigue, and cognitive problems. This suggests NPY could be a useful blood test to help identify ME/CFS and track symptom severity.
Why It Matters
Finding a biological marker for ME/CFS symptom severity could improve diagnosis and treatment monitoring, particularly since the condition is currently diagnosed by clinical criteria alone. This work provides evidence that stress-response system dysregulation is measurable in ME/CFS and offers a potential objective tool to stratify patients and evaluate treatment response.
Observed Findings
Plasma NPY was significantly elevated in CFS patients compared to healthy controls (p = .000)
Plasma NPY was significantly elevated in CFS patients compared to GWI patients (p = .000)
ROC curve analysis showed NPY could distinguish CFS from controls and GWI better than chance alone
In 42 CFS patients with psychometric data, NPY correlated significantly with perceived stress, depression, anger/hostility, confusion, negative thoughts, positive thoughts, general health, and cognitive status
Correlations between NPY and psychometric measures were directionally consistent with hypotheses
Inferred Conclusions
Plasma NPY is elevated in ME/CFS and may serve as a useful biomarker to distinguish CFS from healthy controls and other fatiguing illnesses
NPY levels correlate with multiple symptom domains including stress, mood, cognition, and overall health, suggesting it reflects broad symptom burden
Neuropeptide Y dysregulation indicates involvement of stress-response system abnormalities in ME/CFS pathogenesis and warrants further investigation as a diagnostic or severity marker
Remaining Questions
Does elevated NPY reflect dysregulation of the stress response system that causes symptoms, or is it a secondary consequence of chronic illness?
What This Study Does Not Prove
This study does not establish whether elevated NPY causes ME/CFS symptoms or is merely a consequence of the illness—correlation does not imply causation. It also does not prove NPY is specific to ME/CFS, since only one fatigue comparison group (GWI) was included. The cross-sectional design cannot determine whether NPY changes precede symptom onset or follow from chronic illness.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →